163 related articles for article (PubMed ID: 24366413)
1. Overexpression of O-GlcNAc by prostate cancer cells is significantly associated with poor prognosis of patients.
Kamigaito T; Okaneya T; Kawakubo M; Shimojo H; Nishizawa O; Nakayama J
Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):18-22. PubMed ID: 24366413
[TBL] [Abstract][Full Text] [Related]
2. Critical role of O-Linked β-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis.
Lynch TP; Ferrer CM; Jackson SR; Shahriari KS; Vosseller K; Reginato MJ
J Biol Chem; 2012 Mar; 287(14):11070-81. PubMed ID: 22275356
[TBL] [Abstract][Full Text] [Related]
3. Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1.
Caldwell SA; Jackson SR; Shahriari KS; Lynch TP; Sethi G; Walker S; Vosseller K; Reginato MJ
Oncogene; 2010 May; 29(19):2831-42. PubMed ID: 20190804
[TBL] [Abstract][Full Text] [Related]
4. O-GlcNAcylation is increased in prostate cancer tissues and enhances malignancy of prostate cancer cells.
Gu Y; Gao J; Han C; Zhang X; Liu H; Ma L; Sun X; Yu W
Mol Med Rep; 2014 Aug; 10(2):897-904. PubMed ID: 24865644
[TBL] [Abstract][Full Text] [Related]
5. O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells.
Itkonen HM; Minner S; Guldvik IJ; Sandmann MJ; Tsourlakis MC; Berge V; Svindland A; Schlomm T; Mills IG
Cancer Res; 2013 Aug; 73(16):5277-87. PubMed ID: 23720054
[TBL] [Abstract][Full Text] [Related]
6. High OGT activity is essential for MYC-driven proliferation of prostate cancer cells.
Itkonen HM; Urbanucci A; Martin SE; Khan A; Mathelier A; Thiede B; Walker S; Mills IG
Theranostics; 2019; 9(8):2183-2197. PubMed ID: 31149037
[TBL] [Abstract][Full Text] [Related]
7. Elevated O-GlcNAcylation promotes gastric cancer cells proliferation by modulating cell cycle related proteins and ERK 1/2 signaling.
Jiang M; Qiu Z; Zhang S; Fan X; Cai X; Xu B; Li X; Zhou J; Zhang X; Chu Y; Wang W; Liang J; Horvath T; Yang X; Wu K; Nie Y; Fan D
Oncotarget; 2016 Sep; 7(38):61390-61402. PubMed ID: 27542217
[TBL] [Abstract][Full Text] [Related]
8. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity.
Hua D; Liu MY; Cheng ZD; Qin XJ; Zhang HM; Chen Y; Qin GJ; Liang G; Li JN; Han XF; Liu DX
Mol Immunol; 2009 Sep; 46(15):2876-84. PubMed ID: 19643479
[TBL] [Abstract][Full Text] [Related]
9. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model.
Tollefson MK; Karnes RJ; Kwon ED; Lohse CM; Rangel LJ; Mynderse LA; Cheville JC; Sebo TJ
Mayo Clin Proc; 2014 Mar; 89(3):308-18. PubMed ID: 24486077
[TBL] [Abstract][Full Text] [Related]
11. E. coli sabotages the in vivo production of O-linked β-N-acetylglucosamine-modified proteins.
Goodwin OY; Thomasson MS; Lin AJ; Sweeney MM; Macnaughtan MA
J Biotechnol; 2013 Dec; 168(4):315-23. PubMed ID: 24140293
[TBL] [Abstract][Full Text] [Related]
12. Carcinoma-associated expression of core 2 beta-1,6-N-acetylglucosaminyltransferase gene in human colorectal cancer: role of O-glycans in tumor progression.
Shimodaira K; Nakayama J; Nakamura N; Hasebe O; Katsuyama T; Fukuda M
Cancer Res; 1997 Dec; 57(23):5201-6. PubMed ID: 9393734
[TBL] [Abstract][Full Text] [Related]
13. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.
Zhuo YJ; Xi M; Wan YP; Hua W; Liu YL; Wan S; Zhou YL; Luo HW; Wu SL; Zhong WD; Wu CL
Int J Mol Med; 2015 Apr; 35(4):966-72. PubMed ID: 25647485
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.
Huang Y; Liu X; Wang YH; Yeh SD; Chen CL; Nelson RA; Chu P; Wilson T; Yen Y
Urol Oncol; 2014 Jan; 32(1):51.e9-19. PubMed ID: 24360663
[TBL] [Abstract][Full Text] [Related]
15. MPC1 and MPC2 expressions are associated with favorable clinical outcomes in prostate cancer.
Li X; Ji Y; Han G; Li X; Fan Z; Li Y; Zhong Y; Cao J; Zhao J; Zhang M; Wen J; Goscinski MA; Nesland JM; Suo Z
BMC Cancer; 2016 Nov; 16(1):894. PubMed ID: 27852261
[TBL] [Abstract][Full Text] [Related]
16. FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer.
Gerhardt J; Montani M; Wild P; Beer M; Huber F; Hermanns T; Müntener M; Kristiansen G
Am J Pathol; 2012 Feb; 180(2):848-61. PubMed ID: 22138582
[TBL] [Abstract][Full Text] [Related]
17. The Vav3 oncogene enhances the malignant potential of prostate cancer cells under chronic hypoxia.
Hirai K; Nomura T; Yamasaki M; Inoue T; Narimatsu T; Chisato Nakada PD; Yoshiyuki Tsukamoto PD; Matsuura K; Sato F; Moriyama M; Mimata H
Urol Oncol; 2014 Feb; 32(2):101-9. PubMed ID: 23403204
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
[TBL] [Abstract][Full Text] [Related]
19. [Effect of downregulation of prostate cancer antigen-1 expression on malignant biological behavior of prostate cancer LNCaP cells].
Liu BQ; Wang YK; Wu YD; Wei JX; Li X
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):828-32. PubMed ID: 24447480
[TBL] [Abstract][Full Text] [Related]
20. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis.
Diallo JS; Aldejmah A; Mouhim AF; Fahmy MA; Koumakpayi IH; Sircar K; Bégin LR; Mes-Masson AM; Saad F
BJU Int; 2008 May; 101(10):1302-9. PubMed ID: 18294307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
